To assess SLAMF8 levels in PCa and examine its association with immune cell infiltration, we employed immunohistochemistry to measure the levels of SLAMF8, PD1, CD3, and CD19 in both PCa and benign prostatic hyperplasia (BPH) samples. Here, SLAMF8 is linked to benign prostatic hyperplasia.